|
2018 Journal Article LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancerBoulding, T., McCuaig, R. D., Tan, A., Hardy, K., Wu, F., Dunn, J., Kalimutho, M., Sutton, C. R., Forwood, J. K., Bert, A. G., Goodall, G. J., Malik, L., Yip, D., Dahlstrom, J. E., Zafar, A., Khanna, K. K. and Rao, S. (2018). LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer. Scientific Reports, 8 (1) 73. doi: 10.1038/s41598-017-17913-x |
|
2017 Conference Publication Synergistic inhibition of CEP55 induces mitotic catastrophe and specifically targets aggressive breast cancerSinha, D., Kalimutho, M., Lopez, A. J. and Khanna, K. K. (2017). Synergistic inhibition of CEP55 induces mitotic catastrophe and specifically targets aggressive breast cancer. 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, 8-12 September 2017. Oxford, United Kingdom: OXFORD UNIV. |
|
2017 Conference Publication Targeting thioredoxin reductase 1 in novel combination therapies in p53 mutant triple negative breast cancerRaninga, P., Kalimutho, M., Sinha, D., Bain, A., Tonissen, K. and Khanna, K. K. (2017). Targeting thioredoxin reductase 1 in novel combination therapies in p53 mutant triple negative breast cancer. 42nd European Society for Medical Oncology Congress (ESMO), Madrid, Spain, 8-12 September 2017. Oxford, United Kingdom: Oxford University Press. |
|
2017 Conference Publication Dual inhibition of MEK1/2 and PLK1 specifically targets aggressive breast cancer cell population with CEP55 elevated expressionSinha, Debottam, Kalimutho, Murugan, Lopez, J. Alejandro and Khanna, Kum Kum (2017). Dual inhibition of MEK1/2 and PLK1 specifically targets aggressive breast cancer cell population with CEP55 elevated expression. Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC , United States, 1-5 April 2017. Philadelphia, PA, United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2017-1144 |
|
2017 Journal Article Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiaeKalimutho, Murugan, Bain, Amanda L., Mukherjee, Bipasha, Nag, Purba, Nanayakkara, Devathri M., Harten, Sarah K., Harris, Janelle L., Subramanian, Goutham N., Sinha, Debottam, Shirasawa, Senji, Srihari, Sriganesh, Burma, Sandeep and Khanna, Kum Kum (2017). Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae. Molecular Oncology, 11 (5), 470-490. doi: 10.1002/1878-0261.12040 |
|
2017 Journal Article FBXO31 protects against genomic instability by capping FOXM1 levels at the G2/M transitionJeffery, J. M., Kalimutho, M., Johansson, P., Cardenas, D. G., Kumar, R. and Khanna, K. K. (2017). FBXO31 protects against genomic instability by capping FOXM1 levels at the G2/M transition. Oncogene, 36 (7), 1012-1022. doi: 10.1038/onc.2016.268 |
|
2017 Journal Article The metastasis suppressor RARRES3 as an endogenous inhibitor of the immunoproteasome expression in breast cancer cellsAnderson, Alison M., Kalimutho, Murugan, Harten, Sarah, Nanayakkara, Devathri M., Khanna, Kum Kum and Ragan, Mark A. (2017). The metastasis suppressor RARRES3 as an endogenous inhibitor of the immunoproteasome expression in breast cancer cells. Scientific Reports, 7 (1) 39873. doi: 10.1038/srep39873 |
|
2017 Conference Publication Abstract PR04: Wnt and MAPK pathway activation in conventional and serrated colorectal neoplasiaWhitehall, Vicki, Borowsky, Jennifer, Bond, Catherine, Bettington, Mark, Pearson, Sally-Ann, Kalimutho, Murugan, Liu, John, Dumenil, Troy, McKeone, Diane, Jamieson, Saara, Fernando, Winnie, Fennell, Lochlan, Clouston, Andrew, Rosty, Christophe, Brown, Ian, Walker, Neal and Leggett, Barbara (2017). Abstract PR04: Wnt and MAPK pathway activation in conventional and serrated colorectal neoplasia. AACR Special Conference: Colorectal Cancer: From Initiation to Outcomes, Tampa, FL, United States, 17-20 September 2016. Philadelphia, PA, United States: American Association for Cancer Research. doi: 10.1158/1538-7445.crc16-pr04 |
|
2016 Journal Article RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesisBond, Catherine E., McKeone, Diane M., Kalimutho, Murugan, Bettington, Mark L., Pearson, Sally-Ann, Dumenil, Troy D., Wockner, Leesa F., Burge, Matthew, Leggett, Barbara A. and Whitehall, Vicki L. J. (2016). RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis. Oncotarget, 7 (43), 70589-70600. doi: 10.18632/oncotarget.12130 |
|
2016 Journal Article Adenosine 2B receptor expression on cancer cells promotes metastasisMittal, Deepak, Sinha, Debottam, Barkauskas, Deborah, Young, Arabella, Kalimutho, Murugan, Stannard, Kimberley, Caramia, Franco, Haibe-Kains, Benjamin, Stagg, John, Khanna, Kum Kum, Loi, Sherene and Smyth, Mark J. (2016). Adenosine 2B receptor expression on cancer cells promotes metastasis. Cancer Research, 76 (15), 4372-4382. doi: 10.1158/0008-5472.CAN-16-0544 |
|
2016 Journal Article Understanding the functional impact of copy number alterations in breast cancer using a network modeling approachSrihari, Sriganesh, Kalimutho, Murugan, Lal, Samir, Singla, Jitin, Patel, Dhaval, Simpson, Peter T., Khanna, Kum Kum and Ragan, Mark A. (2016). Understanding the functional impact of copy number alterations in breast cancer using a network modeling approach. Molecular Biosystems, 12 (3), 963-972. doi: 10.1039/C5MB00655D |
|
2016 Journal Article Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancerFrench, Juliet D., Johnatty, Sharon E., Lu, Yi, Beesley, Jonathan, Gao, Bo, Kalimutho, Murugan, Henderson, Michelle J., Russell, Amanda J., Kar, Siddhartha, Chen, Xiaoging, Hillman, Kristine M., Kaufmann, S, Sivakumaran H., O'Reilly, Martin, Wang, Chen, Korbie, Darren J., Lambrechts, Diether, Despierre, Evelyn, Van Nieuwenhuysen, Els, Lambrechts, Sandra, Vergote, Ignace, Karlan, Beth, Lester, Jenny, Orsulic, Sandra, Walsh, Christine, Fasching, Peter A., Beckmann, Matthias W., Ekici, Arif B., Hein, Alexander ... MacGregor, Stuart (2016). Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. Oncotarget, 7 (6), 6353-6368. doi: 10.18632/oncotarget.7047 |
|
2015 Journal Article Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn DiseaseKalimutho, Murugan, Parsons, Kate, Mittal, Deepak, Lopez, J.Alejandro, Srihari, Sriganesh and Khanna, Kum Kum (2015). Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. Trends in Pharmacological Sciences, 36 (12), 822-846. doi: 10.1016/j.tips.2015.08.009 |
|
2015 Journal Article Beyond cytokinesis: the emerging roles of CEP55 in tumorigenesisJeffery, J., Sinha, D., Srihari, S., Kalimutho, M. and Khanna, K. K. (2015). Beyond cytokinesis: the emerging roles of CEP55 in tumorigenesis. Oncogene, 35 (6), 683-690. doi: 10.1038/onc.2015.128 |
|
2015 Conference Publication Effects of the porcupine inhibitor, LGK974, on RNF43 mutant and wild type colorectal cancer cell linesBond, C., Kalimutho, M., Bettington, M., Pearson, S., Leggett, B. and Whitehall, V. (2015). Effects of the porcupine inhibitor, LGK974, on RNF43 mutant and wild type colorectal cancer cell lines. Abstracts of Gastro 2015 GESA‐AGW and WGO International Congress, Gastroenterological Society of Australia Australian Gastroenterology Week 2015 | World Congress of Gastroenterology, Brisbane, QLD, Australia, 28 September‐2 October 2015. Richmond, VIC, Australia: John Wiley & Sons. |
|
2014 Journal Article Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanomade Andrade, Lucas Ferrari, Ngiow, Shin F., Stannard, Kimberly, Rusakiewicz, Sylvie, Kalimutho, Murugan, Khanna, Kum Kum, Tey, Siok-Keen, Takeda, Kazyuoshi, Zitvogel, Laurence, Martinet, Ludovic and Smyth, Mark J. (2014). Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Research, 74 (24), 7298-7308. doi: 10.1158/0008-5472.CAN-14-1339 |
|
2014 Journal Article ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal CancerVan Schaeybroeck, Sandra, Kalimutho, Murugan, Dunne, Philip D., Carson, Robbie, Allen, Wendy, Jithesh, Puthen V., Redmond, Keara L., Sasazuki, Takehiko, Shirasawa, Senji, Blayney, Jaine, Michieli, Paolo, Fenning, Cathy, Lenz, Heinz-Josef, Lawler, Mark, Longley, Daniel B. and Johnston, Patrick G. (2014). ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer. Cell Reports, 7 (6), 1940-1955. doi: 10.1016/j.celrep.2014.05.032 |
|
2014 Journal Article Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinomaAl-Ejeh, Fares, Pajic, Marina, Shi, Wei, Kalimutho, Murugan, Miranda, Mariska, Nagrial, Adnan M., Chou, Angela, Biankin, Andrew V., Grimmond, Sean M., Brown, Michael P. and Khanna, Kum Kum (2014). Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. Clinical Cancer Research, 20 (12), 3187-3197. doi: 10.1158/1078-0432.CCR-14-0048 |
|
2014 Journal Article Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancerAl-Ejeh, F., Simpson, P. T., Sanus, J. M., Klein, K., Kalimutho, M., Shi, W., Miranda, M., Kutasovic, J., Raghavendra, A., Madore, J., Reid, L., Krause, L., Chenevix-Trench, G., Lakhani, S. R. and Khanna, K. K. (2014). Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. Oncogenesis, 3 (4) e100, 1-12. doi: 10.1038/oncsis.2014.14 |
|
2014 Journal Article AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancerDunne, Philip D., McArt, Darragh G., Blayney, Jaine K., Kalimutho, Murugan, Greer, Samanda, Wang, Tingting, Srivastava, Supriya, Ong, Chee Wee, Arthur, Ken, Loughrey, Maurice, Redmond, Keara, Longley, Daniel B., Salto-Tellez, Manuel, Johnston, Patrick G. and Van Schaeybroeck, Sandra (2014). AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clinical Cancer Research, 20 (1), 164-175. doi: 10.1158/1078-0432.CCR-13-1354 |
